8-K: Silexion Therapeutics Shareholders Approve 1-for-9 Reverse Stock Split

Silexion Therapeutics Corp shareholders have approved a 1-for-9 reverse stock split at a reconvened extraordinary general meeting.

Summary

• Silexion Therapeutics Corp held a reconvened extraordinary general meeting on November 19, 2024, after an initial meeting on November 12, 2024, failed to achieve a quorum.
• At the reconvened meeting, approximately 29.5% of the company's outstanding ordinary shares were represented.
• Due to the absence of a majority quorum after a half-hour, the shareholders present were deemed to constitute a quorum for the meeting.
• Shareholders approved a proposal for a 1-for-9 reverse stock split, consolidating existing shares into a smaller number of shares.
• The reverse split will change the par value of the ordinary shares from $0.0001 to $0.0009 per share.
• The proposal was approved by 93.6% of the ordinary shares present and voting, excluding abstentions.

Sentiment

Score: 6

Explanation: The document reports a necessary corporate action (reverse stock split) that was approved by shareholders. While the initial meeting was delayed, the reconvened meeting was successful. The sentiment is neutral to slightly positive as the company is taking steps to maintain its listing.

Positives

• The reverse stock split proposal was approved by a significant majority of voting shareholders (93.6%).
• The company successfully reconvened the meeting and achieved a quorum, albeit a reduced one, to conduct business.

Negatives

• The initial extraordinary general meeting on November 12, 2024, had to be adjourned due to the absence of a quorum.
• Only 29.5% of the company's outstanding ordinary shares were represented at the reconvened meeting.

Risks

• The low shareholder turnout at the reconvened meeting could indicate a lack of engagement or concern among some shareholders.
• Reverse stock splits can sometimes be perceived negatively by the market, potentially impacting the share price.

Future Outlook

The company will proceed with the 1-for-9 reverse stock split, which will consolidate the number of outstanding shares and change the par value.

Management Comments

• The company's CEO, Ilan Hadar, signed the report on behalf of Silexion Therapeutics Corp.

Industry Context

Reverse stock splits are often used by companies to increase their share price and meet minimum listing requirements on exchanges like Nasdaq. This action is not uncommon in the biotech sector, especially for companies with lower share prices.

Comparison to Industry Standards

• Reverse stock splits are a common corporate action, particularly for companies listed on exchanges with minimum share price requirements, such as Nasdaq.
• Many biotech companies with low share prices have undertaken similar reverse stock splits to maintain their listing status or attract institutional investors.
• For example, companies like Cassava Sciences and Ocugen have also implemented reverse stock splits in the past to address low share prices.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the value of their holdings should remain relatively the same immediately after the split.
• The reverse stock split may help the company maintain its Nasdaq listing, which is beneficial for shareholders.

Next Steps

• The company will implement the 1-for-9 reverse stock split.
• The company will likely update shareholders on the effective date of the reverse stock split.

Key Dates

Keywords

reverse stock split, shareholders meeting, quorum, ordinary shares, corporate action, Silexion Therapeutics